Markers of definitive endoderm

• US 9,605,243 B2
• Filed: 10/29/2013
• Issued: 03/28/2017
• Est. Priority Date: 12/23/2003
• Status: Expired due to Fees

• Current Assignee: Viacyte Incorporated (Vertex Pharmaceuticals Incorporated)
• Original Assignee: Viacyte Incorporated (Vertex Pharmaceuticals Incorporated)
• Inventors: D'Amour, Kevin Allen, Agulnick, Alan D., Baetge, Emmanuel Edward
• Primary Examiner(s): Ton, Thaian N
• Assistant Examiner(s): Montanari, David A
• Application Number:
  US14/066,441
• Publication Number:
  US 20140134726A1
• Time in Patent Office: 1,246 Days
• Field of Search: 435/377
• US Class Current: 1/1
• CPC Class Codes: A61K 35/38 Stomach; Intestine; Goblet cells; Oral mucosa; Saliva
• CPC Class Codes: A61K 35/407 Liver; Hepatocytes
• CPC Class Codes: C12N 2501/16 Activin; Inhibin; Mullerian inhibiting substance
• CPC Class Codes: C12N 2501/415 Wnt; Frizzeled
• CPC Class Codes: C12N 5/0603 Embryonic cells production of embryos, nuclear transfer A01K67/027; Embryoid bodies
• CPC Class Codes: C12N 5/0617 Thyroid and parathyroid glands
• CPC Class Codes: C12N 5/0672 Stem cells; Progenitor cells; Precursor cells; Oval cells
• CPC Class Codes: C12N 5/068 Stem cells; Progenitors

Abstract

Disclosed herein are reagent-cell complexes comprising one or more definitive endoderm cells. Also described herein are compositions for detecting definitive endoderm. Method of enriching, isolating and/or purifying definitive endoderm cells are also disclosed.

Claims

1. An in vitro method of producing cells which express thyroid transcription factor 1 (TITF1) from mammalian definitive endoderm cells comprising the steps of:

(i) culturing mammalian definitive endoderm cells with an effective amount of Wnt3a for at least 7 days,

(ii) enriching for cells which express TITF1.

2. The in vitro method of claim 1, wherein step (i) further comprises providing less than 2% serum to the definitive endoderm cells.